KPNA2 and breast cancer: Interestingly, we discovered that the combination of high KPNA2 and low FOXM1 mRNA levels exhibited the most favorable outcomes in terms of overall survival (OS) (p = 0.0355) and disease-specific survival (DSS) (p = 0.0424) (Figure 5b) in HR-positive HER2-negative BC patients.